On April 3, the U.S. Food and Drug Administration (FDA) approved Tanzeum (albiglutide) subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes.
Read more.
FDA approves Tanzeum to treat type 2 diabetes
*Online Bonus Content: This has not been peer reviewed. The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal.
Comments are closed.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
1 Comment.
The purpose of the FDA is to protect and promote the health of the public. However, studies show that the FDA approves many products that are causing tremendous harm to the public’s health. In order for the FDA to function properly and safeguard consumers, it needs to be free from unwarranted pharmaceutical industry and corporation influences. Lack of transparency, corruption, and bias prevents the FDA from carrying out its functions.